AbelZeta Inc.
Clinical trials sponsored by AbelZeta Inc., explained in plain language.
-
Can a single infusion of reprogrammed immune cells quiet lupus kidney disease?
Cure Not yet recruitingThis phase 2 trial is testing whether a single infusion of a patient's own genetically modified immune cells, called C-CAR168, can safely and effectively treat lupus nephritis that has not responded to standard therapies. The cells are designed to target and eliminate specific im…
Phase 2 • Sponsor: AbelZeta Inc. • Aim: Cure
Last updated Sep 12, 2026 00:00 UTC
-
One-Time CAR-T infusion tested against progressive MS
Disease control Not yet recruitingResearchers are testing a one-time CAR-T cell therapy called C-CAR168 in adults with progressive multiple sclerosis that has not responded to standard treatments. The therapy uses a patient's own immune cells, engineered to target two proteins, and is given as a single intravenou…
Phase 1/2 • Sponsor: AbelZeta Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC